MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Momenta Pharmaceuticals Company Profile (NASDAQ:MNTA)

Consensus Ratings for Momenta Pharmaceuticals (NASDAQ:MNTA) (?)
Ratings Breakdown: 4 Hold Rating(s), 5 Buy Rating(s)
Consensus Rating:Buy (Score: 2.56)
Consensus Price Target: $18.78 (83.56% upside)

Analysts' Ratings History for Momenta Pharmaceuticals (NASDAQ:MNTA)
Show:
DateFirmActionRatingPrice TargetActions
6/6/2016Goldman SachsInitiated CoverageNeutral$14.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/4/2016JPMorgan Chase & Co.Reiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/4/2016Brean CapitalReiterated RatingBuy$19.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/4/2016Leerink SwannReiterated RatingOutperform$21.00 -> $18.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/23/2016Cowen and CompanyLower Price Target$20.00 -> $17.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/19/2016Stifel NicolausLower Price TargetBuy$29.00 -> $20.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/18/2016Maxim GroupReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/23/2015BarclaysInitiated CoverageEqual Weight$22.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/24/2015Sanford C. BernsteinReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/28/2014 forward)
Earnings History for Momenta Pharmaceuticals (NASDAQ:MNTA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/2/2016        
5/3/2016Q116($0.32)($0.35)$28.12 million$19.90 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/18/2016Q415($0.04)($0.43)$30.42 million$22.40 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/4/2015Q315($0.19)($0.44)$31.76 million$13.80 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/4/2015Q215($0.39)($0.04)$23.59 million$44.90 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/1/2015Q115($0.48)($0.40)$11.70 million$8.60 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/17/2015Q414($0.26)($0.31)$23.80 million$21.18 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2014Q314($0.43)($0.56)$13.00 million$9.34 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/31/2014Q214($0.46)($0.51)$11.22 million$11.00 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/6/2014Q1($0.55)($0.53)$8.41 million$10.79 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/10/2014Q4($0.45)($0.59)$8.50 million$12.80 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2013Q313($0.48)($0.50)$8.60 million$10.80 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/1/2013Q2 2013($0.45)($0.57)$8.85 million$4.40 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/30/2013Q1 2013($0.44)($0.48)$10.28 million$7.60 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/15/2013Q4 2012($0.41)($0.35)$10.41 million$12.70 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/7/2012Q312($0.27)($0.51)$16.48 million$5.10 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/2/2012($0.17)($0.20)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/3/2012$0.02($0.10)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/9/2012$0.13($0.02)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/7/2011$1.28$1.18ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/4/2011$1.21$1.26ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/5/2011$0.95$1.13ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/10/2011$0.81$0.77ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Momenta Pharmaceuticals (NASDAQ:MNTA)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20161($0.17)($0.17)($0.17)
Q3 20161($0.08)($0.08)($0.08)
Q4 20161$0.02$0.02$0.02
(Data provided by Zacks Investment Research)
Dividend History for Momenta Pharmaceuticals (NASDAQ:MNTA)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Momenta Pharmaceuticals (NASDAQ:MNTA)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
5/20/2016Bruce LeicherSVPSell1,000$10.40$10,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/20/2016Craig A WheelerPresidentSell5,880$10.18$59,858.40View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/20/2016Ganesh Venkataraman KaundinyaVPSell1,050$10.18$10,689.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/20/2016Richard P SheaCFOSell973$10.18$9,905.14View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/19/2016John E BishopVPSell784$10.20$7,996.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/19/2016John E BishopVPSell2,843$9.57$27,207.51View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/23/2016John E BishopVPSell329$9.70$3,191.30View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/22/2016Bruce LeicherSVPSell227$9.65$2,190.55View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/22/2016Craig A WheelerPresidentSell1,688$9.95$16,795.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/22/2016John E BishopVPSell2,848$9.66$27,511.68View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/19/2016Bruce LeicherSVPSell2,000$9.64$19,280.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/19/2016Craig A WheelerPresidentSell9,844$9.37$92,238.28View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/19/2016John E. BishopVPSell357$10.28$3,669.96View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/19/2016Richard P SheaCFOSell1,823$9.64$17,573.72View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/18/2016Bruce LeicherSVPSell337$10.49$3,535.13View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/18/2016James M RoachVPSell272$10.49$2,853.28View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/18/2016Richard P SheaCFOSell183$10.49$1,919.67View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/17/2016Craig A WheelerPresidentSell1,688$11.30$19,074.40View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/11/2015Michael FrankenInsiderSell520$15.84$8,236.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/20/2015Craig A WheelerPresidentSell1,766$17.86$31,540.76View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/19/2015Craig A WheelerPresidentSell2,061$18.05$37,201.05View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/17/2015Craig A WheelerPresidentSell1,766$17.70$31,258.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/5/2015Craig A. WheelerPresidentSell51,667$18.00$930,006.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/20/2015Craig A WheelerPresidentSell1,766$22.28$39,346.48View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/19/2015Craig A WheelerPresidentSell2,061$22.02$45,383.22View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/19/2015James M. RoachVPSell7,011$22.09$154,872.99View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/18/2015James M RoachVPSell6,812$21.80$148,501.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/17/2015Craig A WheelerPresidentSell1,766$21.77$38,445.82View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/15/2015Elizabeth StonerDirectorSell4,570$22.35$102,139.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/19/2015John E BishopVPSell21,274$25.50$542,487.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/18/2015Bruce LeicherSVPSell20,000$23.00$460,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/18/2015Craig A WheelerPresidentSell155,000$24.20$3,751,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/18/2015John E BishopVPSell36,313$23.58$856,260.54View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/4/2015Craig A WheelerPresidentSell103,333$22.00$2,273,326.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/1/2015Bruce LeicherSVPSell40,000$21.00$840,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/1/2015James M RoachVPSell25,000$21.70$542,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/20/2015Craig A WheelerPresidentSell1,766$19.68$34,754.88View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/19/2015Craig A WheelerPresidentSell2,061$19.67$40,539.87View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/23/2015Craig A WheelerPresidentSell51,667$20.00$1,033,340.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/23/2015Ganesh Venkataraman KaundinyaVPSell34,000$19.95$678,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/20/2015Craig A WheelerPresidentSell6,269$18.75$117,543.75View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/17/2015Bruce LeicherSVPSell52,910$19.52$1,032,803.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/16/2015James M RoachVPSell50,000$18.70$935,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/16/2015Richard P SheaCFOSell23,093$15.10$348,704.30View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/5/2015Richard P SheaCFOSell23,364$14.90$348,123.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/24/2015Craig A WheelerPresidentSell2,110$13.52$28,527.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/20/2015Bruce LeicherSVPSell1,891$12.97$24,526.27View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/20/2015Craig A WheelerPresidentSell9,563$13.49$129,004.87View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/20/2015John E BishopVPSell1,768$12.97$22,930.96View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/20/2015Richard P SheaCFOSell1,812$12.97$23,501.64View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/18/2015Craig A WheelerPresidentSell1,688$11.91$20,104.08View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/15/2014Bennett M ShapiroDirectorSell5,800$12.19$70,702.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/11/2014Michael FrankenInsiderSell2,047$12.29$25,157.63View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/1/2014Bennett M ShapiroDirectorSell9,903$12.00$118,836.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/28/2014Bennett M ShapiroDirectorSell1,897$12.00$22,764.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/25/2014Craig A WheelerPresidentSell2,210$11.59$25,613.90View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/20/2014Craig A WheelerPresidentSell1,768$11.10$19,624.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/17/2014Craig A WheelerPresidentSell1,768$10.58$18,705.44View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/3/2014Bennett M ShapiroDirectorSell3,723$12.00$44,676.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/12/2014Peter Barton HuttDirectorSell3,640$11.42$41,568.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/25/2014Craig A WheelerPresidentSell2,209$11.45$25,293.05View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/20/2014Craig A WheelerPresidentSell1,768$11.54$20,402.72View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/15/2014Bennett M ShapiroDirectorSell3,722$12.00$44,664.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/15/2014Craig A WheelerPresidentSell1,768$11.75$20,774.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/13/2014Bennett M ShapiroDirectorSell3,721$12.00$44,652.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/23/2014Craig A WheelerPresidentSell2,110$12.06$25,446.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/20/2014Craig WheelerPresidentSell1,688$12.08$20,391.04View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/15/2014Craig WheelerPresidentSell1,687$11.09$18,708.83View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/25/2014Craig WheelerPresidentSell2,109$17.47$36,844.23View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/24/2014John BishopVPSell1,038$17.67$18,341.46View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/19/2014Craig WheelerPresidentSell3,797$17.90$67,966.30View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/12/2014Ganesh Venkataraman KaundinyaVPSell33,000$17.96$592,680.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/9/2014John BishopVPSell27,159$19.50$529,600.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/25/2013Bruce LeicherSVPSell13,492$18.00$242,856.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/25/2013Craig WheelerPresidentSell2,215$17.77$39,360.55View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/25/2013Ganesh Venkataraman KaundinyaVPSell33,211$18.02$598,462.22View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/19/2013Craig WheelerPresidentSell2,215$17.17$38,031.55View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/15/2013Craig WheelerPresidentSell1,772$16.88$29,911.36View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/11/2013John BishopVPSell5,247$15.46$81,118.62View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/23/2013Craig WheelerPresidentSell2,109$14.90$31,424.10View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/20/2013Craig WheelerPresidentSell2,109$14.47$30,517.23View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/15/2013Craig WheelerPresidentSell1,688$15.43$26,045.84View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/26/2013Richard P SheaCFOSell30,000$16.61$498,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/27/2013Richard P SheaCFOSell10,522$14.61$153,726.42View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/19/2013Richard P SheaCFOSell21,550$14.61$314,845.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/23/2013Craig A WheelerPresidentSell2,109$13.03$27,480.27View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/21/2013Craig A WheelerPresidentSell2,109$12.83$27,058.47View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/15/2013Craig A WheelerPresidentSell1,687$13.33$22,487.71View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/5/2013Elizabeth StonerDirectorSell2,040$14.00$28,560.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/15/2013Bruce LeicherSVPSell1,040$12.26$12,750.40View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Momenta Pharmaceuticals (NASDAQ:MNTA)
DateHeadline
06/28/16 10:04 AMCovering the Bases on Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA): Where is the Stock Going? - Press Telegraph
06/27/16 07:44 AMMomenta Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : MNTA-US : June 27, 2016 -
06/23/16 05:42 PMMomenta Pharmaceuticals Inc. (NASDAQ:MNTA) Stock Momentum at Critical Inflection Point - CML News
06/23/16 07:19 AMMomenta Pharmaceuticals Appoints Steven C. Gilman, Ph.D. to Board of Directors - [at noodls] - 259678e6-528e-446b-92a4-2ab375135763.pdf June 23, 2016 CAMBRIDGE, Mass., June 23, 2016 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization ...
06/23/16 07:17 AMMOMENTA PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers -
06/22/16 03:17 PMMOMENTA PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a -
06/21/16 09:40 AMEarnings Recap: Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) - iStreetWire
06/20/16 05:15 AMMomenta Pharmaceuticals, Inc. (NASDAQ:MNTA) Analyst Price Targets For The Coming Week - Fiscal Standard
06/20/16 04:00 AMVisium Insider-Trading Scheme Brought Down by Tip on Mismarking -
06/17/16 05:03 PMWhich way Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) earnings may go - iStreetWire
06/16/16 05:23 PMVisium's Sanjay Valvani charged with insider trading
06/16/16 12:45 PMVisium Hedge Fund Partner Charged in Insider Trading Case -
06/16/16 09:30 AMEarnings Surprise in Focus: Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) - Investor Newswire
06/15/16 11:48 PMUPDATE 3-Visium's Valvani charged with insider trading on FDA leaks - [Reuters] - A Manhattan hedge fund manager was charged on Wednesday with trading on confidential tips about drug approvals, in one of the biggest insider trading cases since a 2014 court ruling made it harder for U.S. prosecutors to pursue them. U.S. Attorney Preet Bharara in Manhattan accused Sanjay Valvani of Visium Asset Management LP of fraudulently making $25 million by gaining advance word about U.S. Food and Drug Administration approvals of generic drug applications.
06/15/16 05:11 PMU.S. rekindles insider trading push, charges hedge fund's Valvani
06/10/16 08:08 AMMomenta Phama (MNTA) Commences M281 Phase 1
06/09/16 07:29 AMMomenta Pharmaceuticals Initiates Phase 1 Trial of M281, an Anti-FcRn Monoclonal Antibody - [at noodls] - a8fb3d19-f663-44ba-aa5c-d1fb8d196afc.pdf June 9, 2016 CAMBRIDGE, Mass., June 09, 2016 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization ...
06/08/16 05:38 PMMomenta Phama (MNTA) Plans Presentation of Humira Biosimilar at EULAR 2016
06/08/16 07:18 AMMomenta Pharmaceuticals Announces Data Presentation on M923, a Proposed HUMIRA® (adalimumab) Biosimilar, at EULAR 2016 - [at noodls] - 0136aa7b-5428-4e83-922d-666685e158d4.pdf June 8, 2016 CAMBRIDGE, Mass., June 08, 2016 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization ...
06/06/16 08:55 AMMomenta Pharmaceuticals, Inc. (MNTA) Now Covered by Goldman Sachs - Let Me Know About This
06/06/16 06:15 AMCoverage initiated on Momenta Pharma by Goldman -
06/05/16 07:53 AMJPMorgan Chase & Co. Reiterates “Buy” Rating for Momenta Pharmaceuticals, Inc. (MNTA) - Let Me Know About This
06/04/16 08:28 AMMomenta Pharmaceuticals Announces Presentation of Final Data from Phase 1 Trial of Necuparanib in Patients with Pancreatic Cancer at ASCO - [at noodls] - 708972dd-ffdc-4cd5-99cf-36ec559d674e.pdf June 4, 2016 Novel oncology candidate necuparanib had favorable tolerability and encouraging signals of activity in Phase 1 study CAMBRIDGE, Mass., June 04, 2016 ...
06/03/16 08:01 AMStock Review and Earnings Check on Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) - HNN - Stock Review and Earnings Check on Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA)HNNInvestors and analysts are typically super focused on company earnings numbers when they are reported. Company earnings are a good way to evaluate the company profitability. Currently, sell-side analysts are expecting Momenta Pharmaceuticals, Inc.and more »
06/02/16 05:35 PMBrokerages Expect Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) Will Announce Earnings of -$0.29 Per Share - Let Me Know About This - Brokerages Expect Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) Will Announce Earnings of -$0.29 Per ShareLet Me Know About ThisMomenta Pharmaceuticals logo Wall Street analysts expect that Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) will announce earnings of ($0.29) per share for the current fiscal quarter, according to Zacks Investment Research. Four analysts have issued ...Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) topped earnings-per-share estimates 33% of the timeZergwatchMomenta Pharmaceuticals, Inc. (NASDAQ:MNTA) Analyst ReviewRisers & FallersMomenta Pharmaceuticals, Inc. (NASDAQ:MNTA): Price Target ProjectionsNews TribuneThe Post -Stock Tick Tockall 9 news articles »
06/02/16 08:07 AMBiotech Stocks Update: Express Scripts Holding Company (NASDAQ:ESRX) , Momenta Pharmaceuticals, Inc ... - Is stories - Biotech Stocks Update: Express Scripts Holding Company (NASDAQ:ESRX) , Momenta Pharmaceuticals, Inc ...Is storiesIn most recently trading session on 6/1/2016, Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) climbed +1.78% while traded on 1.64 million shares versus it's an average volume of 567.95 thousand shares. The company recorded the last trade with the price ...and more »
06/02/16 08:07 AMAnalyst Earnings Report: Momenta Pharmaceuticals Inc. (NASDAQ:MNTA), PACCAR Inc. (NASDAQ:PCAR) - Beacon Chronicle - Beacon ChronicleAnalyst Earnings Report: Momenta Pharmaceuticals Inc. (NASDAQ:MNTA), PACCAR Inc. (NASDAQ:PCAR)Beacon ChronicleLast Trade: The Company closed its last session at $11.99 with the gain of 1.78%. The market capitalization of the company is $831.99 Million, with the average Volume of 559.11K. The stock currently has its 52-Week High range of $25.56 and 52-week low ...and more »
05/31/16 09:18 AMShare Rating Focus on Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) - HNN - Share Rating Focus on Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA)HNNPresently, Wall Street analysts have given a consensus stock rating of 1.75 on shares of Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA). Covering analysts will typically provide Buy, Sell, or Hold recommendations based on extensive research.and more »
05/29/16 01:31 AMHow Many Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA)'s Analysts Are Bullish? - HNN - How Many Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA)'s Analysts Are Bullish?HNNOut of 9 analysts covering Momenta Pharmaceuticals (NASDAQ:MNTA), 6 rate it a “Buy”, 1 “Sell”, while 3 “Hold”. This means 60% are positive. Momenta Pharmaceuticals has been the topic of 13 analyst reports since August 6, 2015 according to ...Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) Closes At $10.90Vanguard TribuneNew Analyst Ratings On Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA)Risers & FallersIs it Time to Cash in Profits on Momenta Pharmaceuticals Inc. (NASDAQ:MNTA)Franklin Independentall 4 news articles »
05/26/16 10:09 PMEarnings Review and Stock Rundown for Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) - Wall Street Hints and News - Earnings Review and Stock Rundown for Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA)Wall Street Hints and NewsInvestors and analysts will be paying close attention when the company posts earnings results. Earnings numbers can provide insight into a company's overall profitability. Covering equity analysts are expecting Momenta Pharmaceuticals, Inc.and more »
05/26/16 06:08 AMMarket Buzzers Update: Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) , Momenta Pharmaceuticals, Inc. (NASDAQ ... - Street Updates - Market Buzzers Update: Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) , Momenta Pharmaceuticals, Inc. (NASDAQ ...Street UpdatesMomenta Pharmaceuticals, Inc. (NASDAQ:MNTA) moved in green zone with rise of +0.13 points or +1.19% to $11.10. The company has a market worth of $758.72M.Total 438.33 thousand shares were exchanged in last trading session as opposed to average ...and more »
05/25/16 07:16 AMMomenta Pharmaceuticals to Webcast Presentation at the Goldman Sachs 37th Annual Global Healthcare Conference - [at noodls] - 87efa563-0abc-420e-9666-3fb4e005fe64.pdf May 25, 2016 CAMBRIDGE, Mass., May 25, 2016 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization ...
05/22/16 12:17 PMWere Analysts Bullish Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) This Week? - Wall Street Hints and News - Were Analysts Bullish Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) This Week?Wall Street Hints and NewsOut of 9 analysts covering Momenta Pharmaceuticals (NASDAQ:MNTA), 0 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means NaN are positive. Momenta Pharmaceuticals has been the topic of 13 analyst reports since August 6, 2015 according to ...Earnings Quick View: Stanley Black & Decker, Inc. (NYSE:SWH), Silicon Motion Technology Corporation (NASDAQ ...Franklin Independentall 2 news articles »
05/19/16 07:32 AMMomenta Pharmaceuticals Announces Data Presentation on Necuparanib at the 2016 ASCO Annual Meeting - [at noodls] - 72c56c3c-2e78-4563-a64b-6ae82a7ae17d.pdf May 19, 2016 CAMBRIDGE, Mass., May 19, 2016 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization ...
05/09/16 09:26 PMMomenta Pharmaceuticals Inc. (MNTA) Jumps 7.15% on May 09 - Equities.com - NewsWay 21Momenta Pharmaceuticals Inc. (MNTA) Jumps 7.15% on May 09Equities.comMomenta Pharmaceuticals Inc. (MNTA) was among the biggest gainers on the Russell 2000 for Monday May 09 as the stock popped 7.15% to $10.04, representing a gain of $0.67 per share. Some 694,597 shares traded hands on 5,285 trades, compared ...Brean Capital Reaffirms "Buy" Rating for Momenta Pharmaceuticals, Inc. (MNTA)NewsWay 21How Analysts Rated Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) Last Week?Franklin Independentall 6 news articles »
05/09/16 03:15 PMMomenta Pharmaceuticals: Waiting for Fewer Injections - Sales of Glatopa trudge along, but the big opportunity is for the three-times-a-week version of the drug.
05/09/16 12:35 AMNext Weeks Broker Price Targets For Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) - Share Trading News - Next Weeks Broker Price Targets For Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA)Share Trading News02/19/2016 – Momenta Pharmaceuticals, Inc. had its “sell” rating reiterated by analysts at UBS. They now have a USD 9 price target on the stock. 02/19/2016 – Momenta Pharmaceuticals, Inc. had its “overweight” rating reiterated by analysts at JP Morgan.and more »
05/06/16 04:56 PMMOMENTA PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report -
05/05/16 09:59 PMEarnings Outlook on Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) - B.O.D.Y Confidential - Earnings Outlook on Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA)B.O.D.Y ConfidentialAnalysts and investors will be anticipating Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA)'s next earnings release which is expected to be posted on or around 2016-08-02. Sell-side research firms on Wall Street are expecting that the company will post ...and more »
05/05/16 03:13 AMMomenta Pharmaceuticals Inc. (MNTA) Drops 5.84% on May 03 - Equities.com - Momenta Pharmaceuticals Inc. (MNTA) Drops 5.84% on May 03Equities.comMomenta Pharmaceuticals Inc. (MNTA) was one of the Russell 2000's biggest losers for Tuesday May 03 as the stock slid 5.84% to $9.19, a loss of $-0.57 per share. Starting at an opening price of $9.48 a share, the stock traded between $8.82 and $9.62 ...and more »
05/04/16 10:05 PMMomenta (MNTA) Reports Narrower-than-Expected Q1 Loss - Momenta Pharmaceuticals Inc. (MNTA - Analyst Report) reported a loss of 35 cents per share in the first quarter of 2016, narrower than both the Zacks Consensus Estimate of a loss of 38 cents and the year-ago loss of 40 cents. Revenues surged 131.8% to $19 ...
05/04/16 10:55 AMMomenta Pharmaceuticals, Inc. :MNTA-US: Earnings Analysis: Q1, 2016 By the Numbers -
05/03/16 09:10 PMAverage Analyst Rating for Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) - B.O.D.Y Confidential - Average Analyst Rating for Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA)B.O.D.Y ConfidentialWall Street analysts have provided an average broker recommendation of 1.75 on Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) shares. The rating is determined by using the average of all analyst recommendations taken into consideration by Zacks ...and more »
05/03/16 01:46 PMEdited Transcript of MNTA earnings conference call or presentation 3-May-16 1:00pm GMT -
05/03/16 07:30 AMMomenta Pharmaceuticals Reports First Quarter 2016 Financial Results - [at noodls] - c99918a0-e565-4bfc-b1df-f5c064a376d2.pdf May 3, 2016 CAMBRIDGE, Mass., May 03, 2016 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA) today reported its financial results for the first quarter ...
05/03/16 07:26 AMMomenta reports 1Q loss -
05/03/16 07:12 AMMOMENTA PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a -
05/03/16 07:03 AM8:03 am Momenta Pharma misses by $0.01, misses on revs -
05/03/16 06:50 AMMomenta Pharmaceuticals to Webcast Presentation at Two Upcoming Investor Conferences - [at noodls] - f76b31d7-a6d6-4155-8b40-647eda0bf6e6.pdf May 2, 2016 CAMBRIDGE, Mass., April 25, 2016 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization ...
05/03/16 06:07 AMQ1 2016 Momenta Pharmaceuticals Inc Earnings Release - Before Market Open -
About Momenta Pharmaceuticals

Momenta Pharmaceuticals logoMomenta Pharmaceuticals, Inc. (Momenta) is a biotechnology company focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Company has three product areas: Complex Generics, Biosimilars and Novel Therapeutics. The Company's product, a generic version of Lovenox (enoxaparin sodium injection), was approved by the United States Food and Drug Administration. The Company is developing Complex Generics, such as Enoxaparin Sodium Injection and M356. The Company is developing Bosimilars, including M923 and M834. The Company is developing Novel Therapeutics, including Necuparanib. The Company is developing M356 as a generic version of Copaxone. The Company is developing M923, a biosimilar of HUMIRA. The Company is developing M834 as a biosimilar of ORENCIA.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Drugs - Generic
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: MNTA
  • CUSIP: 60877T10
Key Metrics:
  • Previous Close: $9.75
  • 50 Day Moving Average: $10.89
  • 200 Day Moving Average: $11.06
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $695.83M
  • Current Quarter EPS Consensus Estimate: $-1.33 EPS
Additional Links:
Momenta Pharmaceuticals (NASDAQ:MNTA) Chart for Tuesday, June, 28, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha